Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Inventory: 2016-2025

Historic Inventory for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to $8.3 million.

  • UroGen Pharma's Inventory rose 9.84% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 9.84%. This contributed to the annual value of $9.2 million for FY2024, which is 62.65% up from last year.
  • UroGen Pharma's Inventory amounted to $8.3 million in Q3 2025, which was up 17.02% from $7.1 million recorded in Q2 2025.
  • UroGen Pharma's Inventory's 5-year high stood at $9.2 million during Q4 2024, with a 5-year trough of $3.3 million in Q1 2021.
  • For the 3-year period, UroGen Pharma's Inventory averaged around $6.9 million, with its median value being $7.2 million (2024).
  • Per our database at Business Quant, UroGen Pharma's Inventory spiked by 204.09% in 2021 and then decreased by 10.49% in 2022.
  • Quarterly analysis of 5 years shows UroGen Pharma's Inventory stood at $4.8 million in 2021, then declined by 10.49% to $4.3 million in 2022, then soared by 31.17% to $5.7 million in 2023, then soared by 62.65% to $9.2 million in 2024, then rose by 9.84% to $8.3 million in 2025.
  • Its Inventory was $8.3 million in Q3 2025, compared to $7.1 million in Q2 2025 and $7.6 million in Q1 2025.